Compass Therapeutics Q2 net loss widens to $19.9 mln
Overview
Compass Q2 net loss widens to $19.9 mln from $13.1 mln last year
Company ends Q2 with $101 mln cash, runway into 2027
Tovecimig shows fewer deaths than projected in Phase 2/3 study
Outlook
Company expects tovecimig secondary endpoint analysis in Q1 2026
Compass plans CTX-8371 cohort expansions in Q4 2025
Company to file IND for CTX-10726 in Q4 2025
Compass anticipates cash runway into 2027
Result Drivers
G&A - Increased by 20%, primarily due to $1.6 million in additional share-based compensation expense
R&D - Expenses were $16.4 million for the quarter ended June 30, 2025, as compared to $11.2 million for the same period in 2024, an increase of $5.2 million, or 47%.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$19.88 mln |
|
Q2 Basic EPS |
| -$0.14 |
|
Q2 Income From Operations |
| -$21.07 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Compass Therapeutics Inc. is $9.50, about 71.6% above its August 8 closing price of $2.70
Press Release: ID:nGNXwsLW3
Related Articles
Seth Klarman Portfolio
TradingKey - Seth Klarman, the Baupost value investor, long had the distinction of navigating doubt with surgeon-like precision. The technique is married to asymmetric bets, deep margin-of-safety work, and, of course, in many cases, a dash of contrarian genius..jfif)
U.S. Stock Strategy: The Rapid Development of AI Signals a Promising Future
TradingKey - Since Trump announced a 90-day suspension of the "reciprocal tariffs" imposed on certain countries on 9 April this year, all three major U.S. stock indices have recorded significant gains. Looking ahead, against the backdrop of easing global trade frictions.
China July Inflation Commentary: CPI Exceeds Expectations
TradingKey - On 9 August 2025, China's National Bureau of Statistics released inflation data for July. The Consumer Price Index (CPI) rose by 0.4% month-on-month, reversing the previous month's 0.1% decline, while remaining unchanged year-on-year. Core CPI increased by 0.8% year-on-year.
U.S. CPI Preview: Bullish Outlook for U.S. Stocks Continues
TradingKey - On 12 August 2025, the U.S. will release its July CPI data. Market consensus forecasts a year-over-year headline CPI increase of 2.8% and a core CPI rise of 3%, both up 0.1 percentage points from June. We align with these widely held market expectations. Breaking it down by category...
[IN-DEPTH ANALYSIS] LULU: Can it Recover from the Drop?
TradingKey - Thesis Among the stocks of the twenty largest clothing companies by revenue, Lululemon has the fifth lowest forward PE ratio. With all the negative sentiment revolving around the stock, we believe their multiple should be higher.
